Prostatic artery embolization (PAE) is a technically challenging procedure that demands a predictable, targeted, and established microsphere like Embosphere® Microspheres.
Learn More About Embosphere PRO™ Prostatic Artery Embolization Kit
Features & Benefits
CONVENIENT
Merit Medical’s new Embosphere PRO™ Prostatic Artery Embolization Kit combines the power and predictability of Embosphere® Microspheres with basic preparation and delivery tools for added convenience.
Each kit includes:
- (1) prefilled syringe of Embosphere® Microspheres, 300-500μm or 100-300μm
- (1) 10 mL Medallion® Syringe
- (1) 3 mL Medallion® Syringe
- (2) 1 mL Medallion® Syringes
- (1) 3-way Medallion® Stopcock, 1050 psi
PAE Clinical Summary with Embosphere® Microspheres1
A composite database of 286 patients who underwent PAE using Embosphere® Microspheres for treatment of symptomatic benign prostatic hyperplasia (BPH) was analyzed to evaluate clinical outcomes. All patients were suffering from lower urinary tract symptoms (LUTS) due to BPH with International Prostate Symptom Scores (IPSS) of moderate to severe.
Post embolization, 97% of patients reported a decrease in their IPSS by at least 3 points, and 90% of patients dropped at least 1 symptom category, from severe to moderate or moderate to mild.
Most patients also experienced improvement in their Quality of Life score and a substantial decrease in prostate volume.
| Mean Quality of Life at Baseline and Follow Up | ||
| Time Window | Mean ± SD | n |
| Baseline | 4.8 ± 0.9 | 166 |
| 1 to 3 months f/u | 1.4 ± 1.2 | 165 |
| 9 to 16 months f/u | 1.4 ± 1.1 | 116 |
| Mean Prostate Volume at Baseline and Follow Up | ||
| Time Window | Mean ± SD | n |
| Baseline | 85.1 ± 38.3 | 265 |
| 1 to 3 months f/u | 62.4 ± 27.1 | 193 |
| 9 to 16 months f/u | 65.2 ± 28.6 | 118 |
| Mean IPSS at Baseline and Follow Up | ||
| Time Window | Mean ± SD | n |
| Baseline | 21.5 ± 6.8 | 251 |
| 1 to 3 months f/u | 6.3 ± 5.8 | 190 |
| 9 to 16 months f/u | 6.2 ± 5.8 | 136 |
PREDICTABLE
Embosphere® Microspheres temporarily compress to facilitate smooth microcatheter passage (A).2 Once through the microcatheter, Embosphere® Microspheres return to their original spherical shape and stated diameter (B) for predictable, targeted delivery.2
 A |
 B |
TARGETED
Embosphere® Microspheres show a direct correlation between the level of arterial occlusion and the size of the microspheres used, allowing for consistent, targeted occlusion.3,4
ESTABLISHED
Embosphere® Microspheres are the most clinically studied and clinically utilized spherical embolic, having been proven:
- During more than 20 years of clinical use
- In more than 200 clinical articles, with more than 35 PAE-related1
REFERENCES
- Data on file.
- Laurent, et al. Trisacryl Gelatin Microspheres for Therapeutic Embolization, I: Development and In Vitro Evaluation. Am J Neuroradial. 1996 Mar; 17:533-540
- Pelage JP, et al. Uterine Artery Embolization in Sheep: Comparison of Acute Effects with Polyvinyl Alcohol Particles and Calibrated Microspheres. Radiol. 2002;224:436-45
- Verret V, et al. The Arterial Distribution of Embozene and Embosphere Microspheres in Sheep Kidney and Uterus Embolization Models. J Vasc Interv Radiol. 2011 Feb;22(2):220-8
Ordering Information
| Catalog Number | Expanded Family Name | Size Range | Delivery System | Delivery System Size | Color | Carrier Solution | Volume |
|---|---|---|---|---|---|---|---|
| S220PRO | Embosphere® Microspheres | 100-300 µm | Syringe | 20 mL | Yellow | Normal Saline | 2.0 mL |
| S420PRO | Embosphere® Microspheres | 300-500 µm | Syringe | 20 mL | Blue | Normal Saline | 2.0 mL |
